These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32246264)

  • 21. Chronic obstructive pulmonary disease--a treatable disease.
    Osthoff M; Jenkins C; Leuppi J
    Swiss Med Wkly; 2013; 143():w13777. PubMed ID: 23592218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
    Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
    Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M
    Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Worse Prognosis for Stage IA Lung Cancer Patients with Smoking History and More Severe Chronic Obstructive Pulmonary Disease.
    Yoshida Y; Kage H; Murakawa T; Sato Y; Ota S; Fukayama M; Nakajima J
    Ann Thorac Cardiovasc Surg; 2015; 21(3):194-200. PubMed ID: 25641032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease.
    Nichols J
    Pharmacotherapy; 2007 Mar; 27(3):447-54. PubMed ID: 17316155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhaled corticosteroid/beta-2 agonist therapy in moderate COPD].
    Yıldırım N
    Tuberk Toraks; 2010; 58(2):192-201. PubMed ID: 20865575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
    Löfdahl CG; Ericsson A; Svensson K; Andreasson E
    Pharmacoeconomics; 2005; 23(4):365-75. PubMed ID: 15853436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes.
    Bosnic-Anticevich S; Chrystyn H; Costello RW; Dolovich MB; Fletcher MJ; Lavorini F; Rodríguez-Roisin R; Ryan D; Wan Yau Ming S; Price DB
    Int J Chron Obstruct Pulmon Dis; 2017; 12():59-71. PubMed ID: 28053517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis.
    Fitch K; Iwasaki K; Pyenson B; Plauschinat C; Zhang J
    Curr Med Res Opin; 2011 Jul; 27(7):1425-9. PubMed ID: 21599554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort.
    Wei YF; Kuo PH; Tsai YH; Tao CW; Cheng SL; Lee CH; Wu YK; Chen NH; Hsu WH; Hsu JY; Lin MS; Wang CC
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1951-6. PubMed ID: 26392770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S; Eberlein M; Eckhoff J; Schirren J
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.
    Price D; Miravitlles M; Pavord I; Thomas M; Wedzicha J; Haughney J; Bichel K; West D
    NPJ Prim Care Respir Med; 2016 Nov; 26():16061. PubMed ID: 27808096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 2017 Global Initiative for Chronic Obstructive Lung Disease Report and Practice Implications for the Respiratory Therapist.
    Hess MW
    Respir Care; 2017 Nov; 62(11):1492-1500. PubMed ID: 28874610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [25 years of progress in pulmonology: inhalation therapy defeats dyspnoea].
    Gillissen A
    MMW Fortschr Med; 2008 Nov; 150(48):62-4. PubMed ID: 19127625
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of inhaler technique on asthma and COPD control: a multicenter experience.
    Dudvarski Ilic A; Zugic V; Zvezdin B; Kopitovic I; Cekerevac I; Cupurdija V; Perhoc N; Veljkovic V; Barac A
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2509-2517. PubMed ID: 27785007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
    Onoue S; Misaka S; Kawabata Y; Yamada S
    Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.